Imagine a high-tech scanner that acts like a digital magnifying glass for surgeons. Instead of waiting days for a lab to check if all the cancer was removed, this tool uses light and AI to spot remaining tumor cells in under 5 minutes. It's like having a real-time map that tells the doctor exactly where to cut to ensure the patient doesn't need a second surgery.
20% of breast cancer patients undergo unnecessary second surgeries because current margin checks take several days. This increases healthcare costs and patient trauma.
The project is developing an HSI imaging setup, a fiber-optic Raman system, and a pre-trained AI data analysis pipeline.
If you are a surgical imaging equipment provider dealing with the slow turnaround of traditional pathology — this project developed a multimodal optical system that provides feedback on resection margins in less than 5 minutes.
If you are a surgical robotics developer dealing with the lack of real-time tissue differentiation — this project developed an AI-integrated optical tool that can be adapted for robotic/laparoscopic surgery to identify tumors up to 2 mm deep.
If you are a private oncology clinic network dealing with the 20% of breast cancer patients requiring second operations — this project developed a tool to increase sensitivity and specificity to over 95%, reducing hospital stays and complications.
Based on available project data, the specific cost or price of the tool is not mentioned.
The project includes 3 industrial partners and 2 SMEs, suggesting a focus on moving the technology toward industrial application.
Based on available project data, there is no specific information regarding patents or licensing agreements.
It is designed as an intraoperative tool providing actionable feedback in less than 5 minutes, replacing or supplementing the days-long wait for postoperative histopathological analysis.
The project period runs from 2024-12-01 to 2028-11-30, with initial technical deliveries expected at M18.
The consortium is well-balanced for commercialization, featuring a 50% industry ratio with 3 industrial partners and 2 SMEs. With 6 partners across 3 countries (IT, ES, NL), the group combines clinical leadership from the coordinator (Maugeri) with technical and industrial expertise, reducing the gap between research and market entry.
Contact Istituti Clinici Scientifici Maugeri S.p.A.
Contact us to track the M18 delivery of the HSI and Raman prototypes.
